NAD Injection and IV NAD+ in the Research Literature

The gist

A NAD injection delivers NAD+ straight into the body, usually by IV drip, sometimes by a shot under the skin. It is a compounded wellness therapy — mixed by a pharmacy, not approved by the FDA — and it has the thinnest controlled evidence in this whole topic. Two facts shape everything below: infused NAD+ is cleared from the blood very fast, and a compounded injectable NAD+ product was recalled for contamination. This page is a research digest of what studies measured. It is not a recommendation to receive an infusion and gives no dosing instructions.

What Is an NAD Injection

An NAD injection is NAD+ given parenterally — most often as an intravenous (IV) infusion in a wellness or clinic setting, sometimes subcutaneously or intramuscularly as a compounded shot [research context]. Unlike the oral precursors NMN and NR, which the body converts into NAD+, an NAD injection attempts to deliver the coenzyme itself directly into circulation. It is compounded, not FDA-approved, and the peer-reviewed pharmacokinetic data behind it are minimal.

The motivation is intuitive — if tissue NAD+ falls with age ^[5], deliver NAD+ directly. The biology complicates it. NAD+ is large and charged, and most extracellular NAD+ appears to be metabolized before whole cells take it up intact, so an infusion is not simply "filling the tank."

IV NAD+ Therapy: Limited Controlled Evidence

IV NAD+ therapy — often searched as NAD IV therapy — is marketed far ahead of its evidence base. The controlled data are largely pilot and retrospective, not randomized trials, and the most-cited pharmacokinetic observation is striking: in a pilot study, plasma NAD+ was essentially undetectable for roughly the first two hours of infusion before any rise appeared [research context]. A retrospective comparison found IV NAD+ caused more gastrointestinal symptoms and longer infusions than IV NR [research context].

Reported protocols describe multi-hour or multi-day schedules — on the order of hundreds of milligrams over several hours, or repeated daily infusions — but these are study protocols, not clinical recommendations, and the outcome data attached to them are weak. The honest read: among every route for raising NAD+, the injectable one is the least supported by controlled evidence.

Pharmacokinetics: Plasma Clearance and Blood NAD+ Elevation

The NAD+ half life question has no single tidy answer, because the molecule is not freely taken up intact by most cells. What the data do show is that infused IV NAD+ is rapidly cleared from plasma — a pilot study found near-complete plasma removal within roughly the first two hours of infusion [research context]. That rapid clearance is why a fast drip produces discomfort rather than a durable level.

Contrast that with the oral route. Oral precursors are absorbed and raise whole-blood NAD+ over days to weeks, and that elevation persists through chronic dosing in 8–12 week trials — NR held a 22%/51%/142% rise across 8 weeks at 100/300/1000 mg/day ^[4]. So the practical pharmacokinetic picture is two different shapes: a sharp, short-lived spike from infusion versus a slow, sustained climb from oral precursors.

Documented quality risk: the endotoxin recall

Compounded injectable NAD+ carries a contamination risk that is not theoretical. The FDA issued a Class I recall — its most serious category — of a compounded NAD+ injection over elevated bacterial endotoxin [research context]. Reconstituted injectable NAD+ is also chemically fragile: NAD+ is hygroscopic and degrades with heat and moisture, so it must be kept cold and protected from light [research context].

This is the core safety message of the injectable route, and it is the reason this page leads with a careful flag. A compounded, unapproved product with documented contamination history is a different proposition from a capsule swallowed at home, and the literature treats it that way.

Reported infusion-related effects

When IV NAD+ is run too fast, the reported effects are consistent: chest pressure or tightness, abdominal discomfort, flushing and nausea [research context]. In the retrospective pilot, these infusion-related symptoms resolved on completion of the infusion [research context] — they tracked the drip rate rather than lingering. Slowing the infusion is the described mitigation in the protocols, which is itself a tell that the discomfort is rate-driven. None of this is dosing guidance; it is a summary of what was observed and reported.